January 9, 2005 -- During this past week, investors acted like the home-town crowd, which suddenly gets quiet after watching the opposition stop a long drive by intercepting a pass on the two-yard line and running it 98 yards back to score a touchdown. It was a snatching-defeat-from-the-jaws-of-victory sort of thing. Over the five days, the Centient Biotech 200 lost 3.2%, dropping 114 points to close at 3463.91. We discuss three stocks with particularly good announcements: StemCells, which had good news in the lab; Keryx, with good news from trials; and American Pharma Partners, with good news from the FDA.
